San Francisco / Seattle / Station / New York / Evansville / Bethesda / Cary / /
Company
Mead Johnson / IgG / Bayer / Troy AE / LG / Amersham / Proc Natl Acad Sci U S A / Montag AG / K.C. HEROLD AND ASSOCIATES / Donaldson / DCCT Research Group / /
Country
Columbia / /
Currency
pence / / /
Event
FDA Phase / /
Facility
Columbia Presbyterian Medical Center / Northwest Research Institute / National Institute of Diabetes / University of Utah / Columbia University Medical Center / Irving Center / Columbia University / Pediatric Clinical Research Center / University of Chicago / College Station / College of Physicians / University of California / /
adoptive transfer / immunotherapies / immunotherapy / insulin therapy / treatment protocol / immunosuppression / drug therapy / /
Organization
National Cancer Institute / Diabetes Research and Training Center / 3Pacific Northwest Research Institute / University of Utah / Salt Lake City / American Diabetes Association / Columbia University / New York / Irving Center for Clinical Research / the University of Chicago / National Institute of Diabetes and Digestive / Columbia University Medical Center / Division of Endocrinology / University of California at San Francisco / Pediatric Clinical Research Center / College of Physicians and Surgeons / Columbia Presbyterian Medical Center / 2Diabetes Center / Naomi Berrie Diabetes Center / /
A Single Course of Anti-CD3 Monoclonal Antibody hOKT3␥1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes Kevan C. Herold,1 Stephen E. Gi